Review article · 2026 · Open access

Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications

Ali Ahmadi, Ahmed Refaat, Kaiting Miao, Mark Louis P. Vidallon, James D. McFadyen, Xiaowei Wang, Karlheinz Peter

Advanced Drug Delivery Reviews, 239, 115980 · Published 26 October 2026 · DOI 10.1016/j.addr.2026.115980

Open full textCite this paper

In brief

“Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications” is a 2026 review article by Ali Ahmadi and 6 co-authors, published in Advanced Drug Delivery Reviews. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Advanced Drug Delivery Reviews.

Citations
0
References
328
Authors
7

Abstract

Nanoparticles (NPs) have emerged as versatile platforms for drug delivery in cardiovascular diseases (CVDs), demonstrating robust efficacy in preclinical models by stabilizing atherosclerotic plaques, promoting safe and efficient thrombolysis, and mitigating ischemia-reperfusion injury. These advances highlight the maturation of cardiovascular nanomedicine; however, translation to clinical practice remains limited. This gap between laboratory success and clinical adoption reflects broader challenges in nanomedicine design, including suboptimal delivery to diseased tissues, limited efficacy of single therapeutic payload-based strategies in addressing the multifaceted inflammatory pathways driving CVDs, NPs' immunogenicity, and scale-up feasibility. Addressing these barriers is particularly critical in CVDs, where therapeutic success depends on precise engagement with multiple molecular and cellular drivers of disease. This review discusses the evolving landscape of cardiovascular nanomedicine, focusing on four aspects. First, we highlight advances in NPs bioengineering strategies, such as refined targeting moieties, optimized physicochemical properties, and responsiveness to endogenous and external stimuli that enhance organ- and cell-specific delivery in atherosclerosis, myocardial infarction, and stroke. Second, we discuss analytical innovations that improve characterization and control of NPs' biodistribution, enabling more rational targeting. Third, we evaluate therapeutic payloads, emphasizing how RNA-based and immunomodulatory agents represent a meaningful step toward clinical translation. Fourth, we outline approaches to addressing persistent challenges in safety and scalable manufacturing. Together, these developments establish a foundation for translating NP design principles into practical cardiovascular therapies. With continued progress in targeted delivery, clinical safety, and production scalability, cardiovascular nanomedicine is increasingly well-positioned to translate preclinical advances to transformative patient outcomes.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ahmadi, A., Refaat, A., Miao, K., Vidallon, M. L. P., McFadyen, J. D., Wang, X., & Peter, K. (2026). Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications. Advanced Drug Delivery Reviews, 239, 115980. https://doi.org/10.1016/j.addr.2026.115980

MLA 9

Ahmadi, Ali, et al. “Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications.” Advanced Drug Delivery Reviews, vol. 239, 2026, p. 115980. https://doi.org/10.1016/j.addr.2026.115980.

Chicago

Ahmadi, Ali, Ahmed Refaat, Kaiting Miao, Mark Louis P. Vidallon, James D. McFadyen, Xiaowei Wang, and Karlheinz Peter. 2026. “Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications.” Advanced Drug Delivery Reviews 239: 115980. https://doi.org/10.1016/j.addr.2026.115980.

Harvard

Ahmadi, A. et al. (2026) ‘Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications’, Advanced Drug Delivery Reviews, 239, p. 115980. doi:10.1016/j.addr.2026.115980.

IEEE

A. Ahmadi et al., “Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications,” Advanced Drug Delivery Reviews, vol. 239, p. 115980, 2026, doi: 10.1016/j.addr.2026.115980.

BibTeX

@article{ahmadi2026nanoparticles,
  title     = {{Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications}},
  author    = {Ahmadi, Ali and Refaat, Ahmed and Miao, Kaiting and Vidallon, Mark Louis P. and McFadyen, James D. and Wang, Xiaowei and Peter, Karlheinz},
  journal   = {Advanced Drug Delivery Reviews},
  year      = {2026},
  volume    = {239},
  pages     = {115980},
  doi       = {10.1016/j.addr.2026.115980},
  url       = {https://doi.org/10.1016/j.addr.2026.115980}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery

  • nanoparticles
  • drug delivery
  • atherosclerosis
  • thrombolysis
  • ischemia-reperfusion injury
  • myocardial infarction
  • stroke
  • targeted delivery

Work with this paper

Most-cited papers in Materials Science

All highly cited Materials Science papers

Questions about this paper

How do I cite this paper in APA style?

Ahmadi, A., Refaat, A., Miao, K., Vidallon, M. L. P., McFadyen, J. D., Wang, X., & Peter, K. (2026). Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications. Advanced Drug Delivery Reviews, 239, 115980. https://doi.org/10.1016/j.addr.2026.115980

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Advanced Drug Delivery Reviews: sign in and open the full text from this page.

Who wrote this paper?

Ali Ahmadi, Ahmed Refaat, Kaiting Miao, Mark Louis P. Vidallon, James D. McFadyen, Xiaowei Wang, Karlheinz Peter.

What is the DOI of this paper?

10.1016/j.addr.2026.115980, permanently at https://doi.org/10.1016/j.addr.2026.115980. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.